RBPJL

Across TCGA pan-cancer cohorts, RBPJL RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of RBPJL’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where RBPJL RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RBPJL is over-expressed in tumor, although a few such as STAD and COAD show the opposite, repressed pattern.

HNSC, STAD, and LUAD are the cancer types where RBPJL tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RBPJL RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	+0.090	.006	6	view →
STAD	All	All	−0.159	.031	2	view →
LUAD	All	All	+0.098	.011	2	view →
COAD	Female	IV	−0.045	.012	2	view →
KICH	Female	All	−0.038	.006	2	view →
LIHC	All	All	+0.012	.013	2	view →
ESCA	All	All	−1.088	.018	1	view →
LUSC	Male	All	+0.222	.044	1	view →
CHOL	All	All	+0.077	.028	1	view →
BRCA	All	II,III,IV	+0.024	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

RBPJL–HNSC

Open the HNSC breakdown →